News Novo Nordisk leaps on new obesity drug data Shares in Novo Nordisk have risen sharply on new weight-loss data with an injectable formulation of new obesity candidate amycretin.
News High-dose semaglutide ramps up weight loss, says Novo Novo Nordisk's high-dose version of semaglutide boosts its weight-loss ability, but it still can't match its main rival in the obesity market.
News Novo Nordisk swells alliance with AI firm Valo Health Novo Nordisk almost doubles the scale of its R&D alliance with AI specialist Valo Health, which now spans 20 programmes and a value of up to $4.6bn.
News 11 blockbuster drugs to look out for in 2025 Clarivate has revealed 11 drugs due to launch in 2025 that could top $1 billion in annual sales or be clinical 'game changers' in the next five years.
News Novo Nordisk asks FDA not to allow GLP-1 compounding Novo Nordisk has asked the FDA to block compounders from making versions of its older, once-daily GLP-1 agonist liraglutide.
News FDA approves flurry of drugs ahead of holiday season The FDA has wrapped up a series of new approvals as 2024 draws to a close, with Novo Nordisk, Pfizer, Vertex, and Hikma among the beneficiaries.
News Repligen builds in cell therapy with $1.5bn BioLife takeover Repligen has reached a deal to buy cell therapy specialist BioLife Solutions for $1.5bn, tapping into a market growing at breakneck speed.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
